About this Research Topic
Cannabis species (Cannabis spp.) are pharmacologically diverse plants containing myriad distinct compounds, with the two endocannabinoids Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) as prime examples. In humans, the use of cannabis-derived products is increasing globally. Veterinary medicine is dovetailing this trend with growing interest from clients and veterinarians for treating medical conditions in animals with these molecules. In general, CBD is the primary entity of interest in veterinary medicine.
While cannabinoids show considerable therapeutic potential in the management of osteoarthritis, epilepsy, pain and other conditions, there is currently a paucity in adequately controlled studies and data to confirm the safe and effective use in these indications. Considering the current knowledge and research gap, the goal of this Research Topic is to consolidate recent findings and results of high-quality research on the safety and efficacy of cannabis-derivatives in animal species. This in turn will serve as a basis for further discussions and investigations in this growing therapeutic area.
In line with the main goal, this Research Topic focuses on research advances in knowledge and clinical use of cannabis-derivatives in veterinary medicine and welcomes Original Research, Case Reports and Reviews.
Examples of topics that will be considered are:
- Therapeutic use of cannabinoids in animals
- Pharmacokinetic investigations of cannabis-derivatives
- In vivo / in vitro pharmacodynamic studies of molecules associated with cannabis
- Cannabis-related intoxications of animals
- Safety of chronic cannabinoid administration in animals
Robin Temmerman is an employee of Zoetis. James Baumgartner is an employee of Panacea Life Sciences that performs cannabinoid research and produces commercial products in the human and veterinarian wellbeing markets.
While cannabinoids show considerable therapeutic potential in the management of osteoarthritis, epilepsy, pain and other conditions, there is currently a paucity in adequately controlled studies and data to confirm the safe and effective use in these indications. Considering the current knowledge and research gap, the goal of this Research Topic is to consolidate recent findings and results of high-quality research on the safety and efficacy of cannabis-derivatives in animal species. This in turn will serve as a basis for further discussions and investigations in this growing therapeutic area.
In line with the main goal, this Research Topic focuses on research advances in knowledge and clinical use of cannabis-derivatives in veterinary medicine and welcomes Original Research, Case Reports and Reviews.
Examples of topics that will be considered are:
- Therapeutic use of cannabinoids in animals
- Pharmacokinetic investigations of cannabis-derivatives
- In vivo / in vitro pharmacodynamic studies of molecules associated with cannabis
- Cannabis-related intoxications of animals
- Safety of chronic cannabinoid administration in animals
Robin Temmerman is an employee of Zoetis. James Baumgartner is an employee of Panacea Life Sciences that performs cannabinoid research and produces commercial products in the human and veterinarian wellbeing markets.
Keywords: Cannabinoids, Cannabidiol, Dog, Cat, Horse, Epilepsy, Osteoarthritis, Pain
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
